



Ref: Fin-0020/2024

June 11, 2024

The General Manager

Pakistan Stock Exchange Limited
Stock Exchange Building
Stock Exchange Road
Karachi -74000.

SUBJECT: DISCLOSURE OF PRICE SENSITIVE INFORMATION

Dear Sir

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 (a) of the PSX Regulations, we are enclosing herewith a Form, disclosing the following information:

The Board of Directors of Hoechst Pakistan Limited (the Company), in its meeting held today, has accorded its approval to finalize the commercial and legal terms for acquisition of certain products along with associated trademarks from Sanofi affiliates under transfer and assignment agreement(s) (Proposed Transaction). The Proposed Transaction will be executed subject to applicable regulatory approvals, execution of transaction documents and completion of legal formalities.

A disclosure form as required under S.R.O. 143/(1)/2012 dated December 05, 2012 read with Sections 96 and 131 of the Securities Act, 2015 is also enclosed as **Annexure A** hereto.

Yours sincerely



Syed Muhammad Taha Naqvi
Company Secretary

Encl: As above.

Cc:

Director Company Law Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Director Enforcement Department Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Director Securities Market Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad	Executive Director / HOD Offsite-II Department Supervision Division Securities and Exchange Commission of Pakistan NIC Building, Jinnah Avenue Blue Area, Islamabad
--	--	---	---

Annexure A

DISCLOSURE FORM
IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015

Name of Company	Hoechst Pakistan Limited (formerly Sanofi-Aventis Pakistan Limited)
Date of Report	June 11, 2024
Name of Company as specified in The Memorandum	Hoechst Pakistan Limited
Company's Registered Office	Plot 23, Sector 22, Korangi Industrial Area, Karachi-74900
Contact Information	Tel: (021) 35060221-35

Disclosure of inside information by listed company:

The Board of Directors of Hoechst Pakistan Limited (the Company), in its meeting held on June 11, 2024, has accorded its approval to finalize the commercial and legal terms for the acquisition of certain products along with associated trademarks from Sanofi affiliates under transfer and assignment agreement(s) (Proposed Transaction). The Proposed Transaction will be executed subject to applicable regulatory approvals, execution of transaction documents and completion of legal formalities. At present, these products are being marketed/manufactured by the Company under licensing arrangements with Sanofi.

The Board of Directors believe that the Proposed Transaction will be beneficial for the shareholders of the Company in the long run.

Pursuant to the requirements of the Securities Act, 2015, the Company has duly caused this form/statement to be signed on its behalf by the undersigned hereunto duly authorized.

For and on behalf of
Hoechst Pakistan Limited
(formerly Sanofi-Aventis Pakistan Limited)



Syed Muhammad Taha Naqvi
Company Secretary

